Valeant Pharmaceuticals to Acquire Obagi Medical Products

Valeant Pharmaceuticals International is to acquire all of the outstanding common stock of Obagi Medical Products for $19.75 per share in cash, which represents a 28 percent premium to Obagi's closing share price on March 19, 2013, the last trading day prior to announcement. The transaction is expected to close in the first half of 2013.

DealsNorth AmericaUSBriefs